Cambridge Heart Launches Enhanced Website

TEWKSBURY, Mass.--(BUSINESS WIRE)-- Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, launches an updated, feature-rich website today at www.cambridgeheart.com. The new site features updated content in a variety of multimedia formats and addresses the company’s key audiences including clinicians, patients and investors. New graphics, increased functionality and improved navigation to allow users to easily access important information about sudden cardiac arrest and to learn about Cambridge Heart’s proprietary Microvolt T-Wave Alternans™ (MTWA) diagnostic test. Patients can now use the website to locate testing facilities in their area that offer the MTWA test.

“As the MTWA test continues to be embraced by the medical community through our partnership with Cardiac Science, it is important that we provide a resource for clinicians and patients who are interested in learning more about how MTWA testing can help identifying and managing patients at risk for sudden cardiac arrest,” said Ali Haghighi-Mood, CEO, Cambridge Heart.

The new website also includes a clinician resource center which features Cambridge Heart product information, clinical data on MTWA and case studies demonstrating the utility of the company’s technology.

Sudden Cardiac Arrest (SCA) is the leading cause of death in the U.S. accounting for an estimated 300,000 deaths each year - more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8 percent, making prediction and prevention critically important. It is estimated that there are approximately 10 to 12 million heart attack and heart failure patients in the U.S. who can benefit from annual MTWA testing. Microvolt T-Wave Alternans is a marker of SCA risk which is measured during a non-invasive treadmill test using Cambridge Heart's proprietary technologies. The Company's MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy.

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans measurement technologies, including the patented Analytic Spectral Method® and ultrasensitive disposable electrode sensors. The Company’s MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.

http://www.cambridgeheart.com.

Statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences are identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.



CONTACT:

At Cambridge Heart:
Vincenzo LiCausi, 978-654-7600 x 6645
Chief Financial Officer
[email protected]
or
Media:
KOGS Communication
Edna Kaplan, 781-639-1910
[email protected]
or
Investor Relations:
Wolfe Axelrod Weinberger Associates, LLC
Stephen D. Axelrod, CFA
Diana Bittner (general inquiries)
212-370-4500
[email protected]
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Technology  Hardware  Software  Health  Biotechnology  Cardiology  Hospitals  Medical Devices

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.